Výsledky vyhledávání - "Petra Fettes"

Akademický článek

504 A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

Externí odkaz: https://doaj.org/article/d5a96bb3d08046198909460995d070a4

Zobrazit plný text záznamu

Akademický článek

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery.

Autor: Norbert Pfeiffer, Bogomil Voykov, Giulia Renieri, Katharina Bell, Paul Richter, Melanie Weigel, Hagen Thieme, Barbara Wilhelm, Katrin Lorenz, Martin Feindor, Katja Wosikowski, Michel Janicot, Daniela Päckert, Regina Römmich, Carola Mala, Petra Fettes, Eugen Leo

Publikováno v: PLoS ONE, Vol 12, Iss 11, p e0188899 (2017)

To evaluate the safety and tolerability of intravitreal ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in patients with primary open angle glaucoma (POAG) undergoing trabeculectomy (TE; glauc

Externí odkaz: https://doaj.org/article/5b269b6322544aeb927497877deed479

Zobrazit plný text záznamu

Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER)

Autor: Andrea Necchi, Roberto Iacovelli, Massimo Di Maio, Paolo Gontero, Petra Fettes, Kathrin Klar, Frank Hermann, Eugen Leo

Publikováno v: Journal of Clinical Oncology. 41:TPS595-TPS595

TPS595 Background: Neoadjuvant chemotherapy (NACT) is a well-established treatment modality in MIBC but suffers from limited activity and significant toxicity. Recently, neoadjuvant immunotherapy (I/O) has demonstrated clinical safety and efficacy in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2db231f8a4b5615db00b4f8ab0e05a1a
https://doi.org/10.1200/jco.2023.41.6_suppl.tps595

Zobrazit plný text záznamu

504 A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundGrowth and differentiation factor 15 (GDF-15) is a TGF-β superfamily member physiologically expressed mainly in placenta and linked to feto-maternal tolerance. Under pathophysiologic conditions, prevention of excessive immune cell infiltra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d90eee49c9b286d3e75872b7dc28b9
https://doaj.org/article/d5a96bb3d08046198909460995d070a4

Zobrazit plný text záznamu

Abstract P06-01: A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Publikováno v: Molecular Cancer Therapeutics. 20:P06-01

Background: Growth and differentiation factor 15 (GDF-15) is a TGF-β superfamily member physiologically expressed mainly in placenta and linked to feto-maternal tolerance. Under pathophysiologic conditions, prevention of excessive immune cell infilt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5e5e2484130ef9b71fc196d1493dcdb
https://doi.org/10.1158/1535-7163.targ-21-p06-01

Zobrazit plný text záznamu

A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER)

Publikováno v: Journal of Clinical Oncology. 39:TPS2658-TPS2658

TPS2658 Background: Growth and differentiation factor 15 (GDF-15) is a TGF-β superfamily member physiologically expressed mainly in placenta and linked to feto-maternal tolerance. Under pathophysiologic conditions, prevention of excessive immune cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::634a0c9eca1c84d1e6ed28e755ac0e0a
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2658

Zobrazit plný text záznamu

Autor: Martin Feindor, Bogomil Voykov, Melanie Weigel, Katharina Bell, Hagen Thieme, Paul Richter, Katrin Lorenz, Regina Römmich, Michel Janicot, Barbara Wilhelm, Giulia Renieri, Katja Wosikowski, Petra Fettes, Daniela Päckert, Eugen Leo, Carola Mala, Norbert Pfeiffer

Publikováno v: PLoS ONE, Vol 12, Iss 11, p e0188899 (2017)
PLoS ONE

PURPOSE To evaluate the safety and tolerability of intravitreal ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in patients with primary open angle glaucoma (POAG) undergoing trabeculectomy (T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07fe8f3eb7a4c6d2b878716b47260b10
http://europepmc.org/articles/PMC5708654?pdf=render

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání